Skip to content

Clinical trials

Phase 3 Polyradiculoneuropathy, Chronic Inflammatory Demyelinating trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Phase: Phase 3 Clear all

28 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20042
20101
20122
20131
20141
20153
20161
20171
20191
20221
20243
20256
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed15
Recruiting8
Active, not recruiting1
Terminated1
Unknown status1
Not yet recruiting1
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
CSL Behring3
National Center for Research Resources (NCRR)3
Sanofi3
Baxalta now part of Shire2
Grifols Therapeutics LLC2
Laboratoire français de Fractionnement et de Biotechnologies2
Takeda2
argenx2
Amsterdam University Medical Center (UMC), Location Academic Medical Center (AMC)1
Centre Hospitalier Universitaire de Saint Etienne1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating28
Rare Diseases5
Mental Disorders3
Neurologic Manifestations3
Peripheral Nervous System Diseases3
Autoimmune Diseases of the Nervous System2
Nervous System Diseases2
Polyradiculoneuropathy2
Autoimmune Diseases1
Demyelinating Diseases1

Trials

Showing 26 to 28 of 28. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.